A Phase 4 interventional study of Dronedarone and Placebo (for Dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 92 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2013-04-11.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 17th largest by enrollment, is one of 9 that started in 2010, is one of 11 in phase 4, and was the 9th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is below the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
23 studies in Atrial Fibrillation by Sanofi: none open now, none under way, none of them phase 3. Of 23 finished, 7 (30%) have results posted.
Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2010, is one of 6 in phase 4, and was the 17th registered.
Sanofi’s Atrial Fibrillation studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 23 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective was to evaluate the effects of dronedarone on Atrial Fibrillation (AF) burden (i.e. percent time in AF) as measured on electrogram (EGM) in subjects with a permanent pacemaker.
Secondary objectives were to evaluate:
The maximum duration of the study period for a participant was 18 weeks (approximatively 4.5 months) including up to 4 weeks screening, 12-week Treatment period and a post-treatment follow-up of 2 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dronedarone 400 mg twice a day for 12 weeks
Drug: Dronedarone
Placebo (for Dronedarone) twice a day for 12 weeks
Drug: Placebo (for Dronedarone)
Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)
Also known as: Multaq®, SR33589
Film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)
Atrial Fibrillation (AF) Burden During the 12-week Treatment Period
AF burden, defined as the percent time a subject is in AF, was evaluated centrally by a Pacemaker Core Lab based on pacemaker interrogation reports including Electrogram (EGM) data provided by the Investigator. AF burden during the 12-week treatment period was defined as the duration-weighted average of AF burden collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.
Time frame: Baseline (before randomization), 4 weeks and 12 weeks after randomization
AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment
AF burden at each pacemaker interrogation as evaluated centrally by the Pacemaker Core Lab
Time frame: 4 weeks and 12 weeks after randomization
Average Ventricular Rate During AF Episodes
Ventricular rates of AF episodes were obtained from pacemaker interrogation and EGM review. The average ventricular rate during AF episodes in the 12-week treatment period was defined as the duration-weighted average of the ventricular rates collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.
Time frame: Baseline (before randomization), 4 weeks and 12 weeks after randomization
Atrial Fibrillation Severity Scale (AFSS) Scores
The University of Toronto Atrial Fibrillation Severity Scale is an instrument to assess the subject-perceived AF burden and AF symptom severity. It consists in a questionnaire plus a scoring algorithm. AF Burden score ranges from 3 to 30 and higher scores indicate greater AF burden. AF symptoms severity score ranges from 0 to 35 and higher scores indicate extremely severe AF symptoms.
Time frame: Baseline (before randomization) and 12 weeks after randomization
Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)
Electrical cardioversion is a procedure in which an electric shock is used to restore normal heart rhythm. Overdrive pacing is a procedure in which an artificial cardiac pacemaker is used to increase the heart rate in order to suppress certain arrhythmias. Incidence rate of electrical cardioversion (or overdrive pacing) is expressed as the number of participants that was cardioverted or paced during the study.
Time frame: 12 weeks
Overview of Adverse Events (AE)
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
Time frame: from first study drug intake up to 10 days after the last study drug intake
Recruitment initiated in July 2010 was discontinued in December, 2011 due to significantly lower than planned enrollment with no feasibility to complete the trial within reasonable, meaningful timelines and despite a protocol amendment that extended the recruitment period and reduced the sample size from 424 to 286 participants.
| Milestone | Placebo | Dronedarone |
|---|---|---|
| Started | 55 | 57 |
| Treated | 55 | 57 |
| Evaluable for efficacy | 55 | 55 |
| Completed | 49 | 45 |
| Not completed | 6 | 12 |
| Withdrew: Adverse event | 3 | 8 |
| Withdrew: Other than above | 3 | 4 |
AF burden, defined as the percent time a subject is in AF, was evaluated centrally by a Pacemaker Core Lab based on pacemaker interrogation reports including Electrogram (EGM) data provided by the Investigator. AF burden during the 12-week treatment period was defined as the duration-weighted average of AF burden collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.
| percent time in AF | Placebo | Dronedarone |
|---|---|---|
| Baseline | 8.77 (6.413 to 12.006) | 10.14 (7.167 to 14.354) |
| 12-week treatment period | 9.90 (6.633 to 14.772) | 4.63 (2.610 to 8.198) |
AF burden at each pacemaker interrogation as evaluated centrally by the Pacemaker Core Lab
| percent time in AF | Placebo | Dronedarone |
|---|---|---|
| Week 1 - 4 (n =54, 49) | 8.99 (5.901 to 13.705) | 3.62 (1.806 to 7.258) |
| Week 5 - 12 (n =54, 54) | 9.37 (5.938 to 14.786) | 4.28 (2.388 to 7.673) |
Ventricular rates of AF episodes were obtained from pacemaker interrogation and EGM review. The average ventricular rate during AF episodes in the 12-week treatment period was defined as the duration-weighted average of the ventricular rates collected at Week 4 and Week 12. It was calculated from the single available measurement when one measurement was missing.
| beats/min | Placebo | Dronedarone |
|---|---|---|
| Baseline (n =49, 47) | 93.02 ± 16.74 | 90.68 ± 19.80 |
| Week 1-12 (n =49, 48) | 95.67 ± 17.43 | 91.28 ± 20.30 |
| --- Week 1-4 (n =44, 41) | 96.80 ± 20.09 | 91.93 ± 21.89 |
| --- Week 5-12 (n =47, 42) | 95.58 ± 18.72 | 88.56 ± 20.69 |
The University of Toronto Atrial Fibrillation Severity Scale is an instrument to assess the subject-perceived AF burden and AF symptom severity. It consists in a questionnaire plus a scoring algorithm. AF Burden score ranges from 3 to 30 and higher scores indicate greater AF burden. AF symptoms severity score ranges from 0 to 35 and higher scores indicate extremely severe AF symptoms.
| units on a scale | Placebo | Dronedarone |
|---|---|---|
| AF burden at baseline (n =45, 34) | 13.72 ± 4.59 | 12.76 ± 4.62 |
| AF burden after 12-week treatment (n =38, 31) | 13.30 ± 5.40 | 12.48 ± 5.45 |
| AF symptoms at baseline (n =55, 55) | 8.47 ± 6.97 | 8.36 ± 6.83 |
| AF symptoms after 12-week treatment (n =54, 53) | 8.06 ± 7.11 | 7.42 ± 7.48 |
Electrical cardioversion is a procedure in which an electric shock is used to restore normal heart rhythm. Overdrive pacing is a procedure in which an artificial cardiac pacemaker is used to increase the heart rate in order to suppress certain arrhythmias. Incidence rate of electrical cardioversion (or overdrive pacing) is expressed as the number of participants that was cardioverted or paced during the study.
| participants | Placebo | Dronedarone |
|---|---|---|
| Incidence Rate of Electrical Cardioversion (or Overdrive Pacing) | 1 | 0 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.
| participants | Placebo | Dronedarone |
|---|---|---|
| Any AE | 31 | 37 |
| - Any serious AE | 7 | 7 |
| - Any AE leading to death | 0 | 0 |
| - Any AE leading to treatment discontinuation | 3 | 8 |
Collected over All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug in the period spanning from signature of the Informed Consent Form up to the last visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/55 (12.7%) | 9/55 (16.4%) |
| Dronedarone | — | 7/57 (12.3%) | 16/57 (28.1%) |
| Event | Placebo | Dronedarone |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/55 | 3/57 |
| Lobar pneumoniaInfections and infestations | 1/55 | 0/57 |
| Intracardiac thrombusCardiac disorders | 1/55 | 0/57 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/55 | 0/57 |
| DiarrhoeaGastrointestinal disorders | 1/55 | 0/57 |
| MelaenaGastrointestinal disorders | 1/55 | 0/57 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/55 | 0/57 |
| Non-cardiac chest painGeneral disorders | 1/55 | 0/57 |
| Neuropathy peripheralNervous system disorders | 0/55 | 1/57 |
| PresyncopeNervous system disorders | 0/55 | 1/57 |
| Event | Placebo | Dronedarone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/55 | 7/57 |
| NauseaGastrointestinal disorders | 1/55 | 7/57 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/55 | 2/57 |
| DizzinessNervous system disorders | 2/55 | 3/57 |
| FatigueGeneral disorders | 1/55 | 3/57 |
| Age Continuous(years) | Placebo | Dronedarone | Total |
|---|---|---|---|
| Mean | 74.5 ± 9.5 | 77.3 ± 8.6 | 75.9 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo | Dronedarone | Total |
|---|---|---|---|
| Female | 17 | 28 | 45 |
| Male | 38 | 29 | 67 |
The record gives a start of Jul 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronedarone